- The investment round was led by Intervest as the financial investor and the Samsung Life Science Fund as the strategic
investor, with DS Asset Management and Mint Venture Partners joining as new investors.
- The proceeds will be used to support the clinical preparation and development of the FGFR3-targeting ADC, AMB302, as
well as the advancement of follow-up pipeline programs targeting brain diseases.
Link to full news: https://www.mk.co.kr/en/it/11080813